Union Bank Backs Kashiv BioSciences in ₹648Cr Expansion Deal

Kashiv BioSciences, a leading biopharmaceutical company, has secured ₹648 crore in financing from Union Bank of India to expand its manufacturing capabilities. The funding will support the development of a state-of-the-art, single-use commercial manufacturing facility at Pipan, near Ahmedabad, Gujarat.

Designed as one of the largest facilities of its kind in India, the new plant will be equipped with advanced technologies to enable the production of high-quality biologics and specialty pharmaceuticals. Once fully operational, the facility will have a manufacturing capacity of up to 50,000 litres.

This expansion represents a key milestone in Kashiv BioSciences’ global growth strategy and is expected to strengthen India’s position as a hub for advanced biopharmaceutical manufacturing. Serving regulated markets including the US, Canada, Europe, and other regions, the facility will also generate significant employment opportunities across scientific, technical, and operational roles, further reinforcing India’s role in the global pharmaceutical ecosystem.

News by Rahul Yelligetti.